Cited 24 times in
Recurrence Risk-Scoring Model for Stage I Adenocarcinoma of the Lung
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정경영 | - |
dc.date.accessioned | 2016-02-04T12:03:29Z | - |
dc.date.available | 2016-02-04T12:03:29Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1068-9265 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/141796 | - |
dc.description.abstract | PURPOSE: The aim of this retrospective, multicenter study was to develop a recurrence risk-scoring model in patients with curatively resected stage I lung adenocarcinoma (ADC). METHODS: Clinicopathologic and outcome data for a development cohort of 1,700 patients with pathologic stage I ADC from four institutions resected between January 2000 and December 2009 were evaluated. A phantom study was performed for correction of inter-institutional differences in positron emission tomography-standardized uptake value (PET-SUV). A nomogram for recurrence prediction was developed using Cox proportional hazards regression. This model was validated in a cohort of 460 patients in two other hospitals. The recurrence rate was 21.0 % for the development cohort and 22.1 % for the validation cohort. RESULTS: In multivariable analysis, three independent predictors for recurrence were identified: pathologic tumor size (hazard ratio [HR] 1.03, 95 % CI 1.017-1.048; p < 0.001), corrected PET-SUV (HR 1.08, 95 % CI 1.051-1.105; p < 0.001), and lymphovascular invasion (HR 1.65, 95 % CI 1.17-2.33; p = 0.004). The nomogram was made based on these factors and a calculated risk score was accorded to each patient. Kaplan-Meier analysis of the development cohort showed a 5-year recurrence-free survival (RFS) of 83 % (95 % CI 0.80-0.86) in low-risk patients and 59 % (95 % CI 0.54-0.66) in high-risk patients with the highest 30 percentile scores. The concordance index was 0.632 by external validation. CONCLUSIONS: This recurrence risk-scoring model can be used to predict the RFS for pathologic stage I ADC patients using the above three easily measurable factors. High-risk patients need close follow-up and can be candidates for adjuvant chemotherapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 4089~4097 | - |
dc.relation.isPartOf | ANNALS OF SURGICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenocarcinoma/diagnostic imaging | - |
dc.subject.MESH | Adenocarcinoma/pathology* | - |
dc.subject.MESH | Adenocarcinoma/surgery | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Blood Vessels/pathology | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms/diagnostic imaging | - |
dc.subject.MESH | Lung Neoplasms/pathology* | - |
dc.subject.MESH | Lung Neoplasms/surgery | - |
dc.subject.MESH | Lymphatic Vessels/pathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Invasiveness | - |
dc.subject.MESH | Neoplasm Recurrence, Local/epidemiology* | - |
dc.subject.MESH | Nomograms* | - |
dc.subject.MESH | Positron-Emission Tomography | - |
dc.subject.MESH | Proportional Hazards Models | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Risk Assessment | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Tumor Burden | - |
dc.title | Recurrence Risk-Scoring Model for Stage I Adenocarcinoma of the Lung | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Thoracic & Cardiovascular Surgery (흉부외과학) | - |
dc.contributor.googleauthor | Hee Chul Yang | - |
dc.contributor.googleauthor | Hyeong Ryul Kim | - |
dc.contributor.googleauthor | Jae Yong Park | - |
dc.contributor.googleauthor | Ju Sik Yun | - |
dc.contributor.googleauthor | Kook Joo Na | - |
dc.contributor.googleauthor | Young Mog Shim | - |
dc.contributor.googleauthor | Jhingook Kim | - |
dc.contributor.googleauthor | Jong Mog Lee | - |
dc.contributor.googleauthor | Moon Soo Kim | - |
dc.contributor.googleauthor | Jae Ill Zo | - |
dc.contributor.googleauthor | Se Hoon Choi | - |
dc.contributor.googleauthor | Dong Kwan Kim | - |
dc.contributor.googleauthor | Seong Yong Park | - |
dc.contributor.googleauthor | Mi Kyung Bae | - |
dc.contributor.googleauthor | Kyung Young Chung | - |
dc.contributor.googleauthor | Jin-Haeng Chung | - |
dc.contributor.googleauthor | Ho-Young Lee | - |
dc.contributor.googleauthor | Soyeon Ahn | - |
dc.contributor.googleauthor | Sukki Cho | - |
dc.contributor.googleauthor | Kwhanmien Kim | - |
dc.contributor.googleauthor | Sanghoon Jheon | - |
dc.identifier.doi | 10.1245/s10434-015-4411-9 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03571 | - |
dc.relation.journalcode | J00179 | - |
dc.identifier.eissn | 1534-4681 | - |
dc.identifier.pmid | 25783676 | - |
dc.identifier.url | http://link.springer.com/article/10.1245%2Fs10434-015-4411-9 | - |
dc.subject.keyword | Locoregional Recurrence | - |
dc.subject.keyword | Validation Cohort | - |
dc.subject.keyword | Phantom Study | - |
dc.subject.keyword | Concordance Index | - |
dc.subject.keyword | Pathologic Tumor Size | - |
dc.contributor.alternativeName | Chung, Kyung Young | - |
dc.contributor.affiliatedAuthor | Chung, Kyung Young | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 22 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 4089 | - |
dc.citation.endPage | 4097 | - |
dc.identifier.bibliographicCitation | ANNALS OF SURGICAL ONCOLOGY, Vol.22(12) : 4089-4097, 2015 | - |
dc.identifier.rimsid | 30896 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.